4SC Investor
4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases.
Founded Date:
1997
Total Funding:
94700000 EUR
Employee Number:
51-100
Funding Status:
IPO
Last Funding Type:
Post-IPO Equity
Investors Number:
9
Last Funding Date:
2019-11-12
Industry:
Energetic Process
Headquarters:
Germany
Estimated Revenue:
$1M to $10M